Pharma Focus America

Inocras and Massive Bio Announce Revolutionary Collaboration in Cancer Care, Leveraging Whole-Genome Insights and Clinical Trial Matching

Wednesday, June 05, 2024

Inocras, a leading company specializing in AI-driven whole genome testing, and Massive Bio, a provider of cutting-edge AI-driven clinical trial matching platforms, have joined forces to revolutionize cancer patient care. This collaboration aims to enhance personalized care for cancer patients by leveraging Inocras's expertise in whole genome sequencing (WGS) and bioinformatics alongside Massive Bio's advanced AI technology for clinical trial matching.

The partnership focuses on providing comprehensive genetic testing using whole genome sequencing while also supporting clinical trial matching for patients and healthcare providers. This means patients can learn about future clinical trials without needing additional genetic tests, thanks to the extensive data generated by whole genome sequencing.

Inocras is at the forefront of advanced whole genome testing, capable of identifying rare and complex mutations often missed by traditional genetic tests. To make whole genome testing more accessible, Inocras recently launched a user-friendly digital platform.

Inocras, highlights the importance of the partnership, stating that while Inocras excels in WGS testing, not all patients have treatment options aligned with their biomarkers. Clinical trials offer hope for these patients, and partnering with Massive Bio enriches their biomarker data, facilitating more precise patient matching with effective clinical trials, all accessible through a single digital platform.

Massive Bio is building a large global network in oncology/hematology to transform patient recruitment. Their real-time AI-driven platform, Synergy-AI, matches patients with over 14,000 clinical trials instantly, significantly reducing screen failures and maximizing trial enrollment potential.

Massive Bio, emphasizes the significance of the partnership, noting that they are setting a new standard in cancer care by prioritizing a data-driven, patient-centric approach. By leveraging AI and advanced genomic testing, they aim to increase access to precision medicine for cancer patients, tailored to each patient's unique genetic profile.

The combined expertise and innovative solutions of both companies promise to usher in a new era of personalized cancer care. Together, they are forging a transformative path for cancer patients.

 

Source: businesswire.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024